Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Biotime Inc (BTX)

Biotime Inc (BTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
BioTime Reports Second Quarter 2019 Financial Results and Provides Business Update

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cellular therapies for unmet medical needs, reported financial and operating results for the second...

BTX : 0.92 (-7.08%)
BioTime to Report Second Quarter 2019 Financial Results and Provide Business Update on August 8, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced that it will report its second quarter 2019...

BTX : 0.92 (-7.08%)
BioTime Announces Name Change to Lineage Cell Therapeutics

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is launching a new corporate brand, including...

BTX : 0.92 (-7.08%)
BioTime Initiates Dosing in Phase I/IIa Clinical Study of OpRegen for Treatment of Dry-AMD Utilizing Orbit Subretinal Delivery System

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, today announced that it has dosed its first patient with the Orbit...

BTX : 0.92 (-7.08%)
Biotime Inc Set to Possibly Rebound After Yesterday's Selloff of 4.39%

Biotime Inc (AMEX:BTX) traded in a range yesterday that spanned from a low of $1.04 to a high of $1.10. Yesterday, the shares fell 4.4%, which took the trading range below the 3-day low of $1.12 on volume...

BTX : 0.92 (-7.08%)
Achillion (ACHN) Reports Wider-Than-Expected Loss in Q1

Achillion (ACHN) reports narrower year-over-year loss in Q1. The absence of an approved product results in no revenues in the quarter.

ALXN : 106.97 (+1.59%)
BTX : 0.92 (-7.08%)
ACHN : 6.76 (+10.28%)
ANIK : 45.21 (+1.69%)
BioTime Awarded $2.5 Million Grant from the Israel Innovation Authority for Continued Development of OpRegen(R)

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, has been awarded a new research & development grant...

BTX : 0.92 (-7.08%)
BioTime (BTX) Tops Q1 Earnings and Revenue Estimates

BioTime (BTX) delivered earnings and revenue surprises of 600.00% and 40.61%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

BTX : 0.92 (-7.08%)
BioTime Reports First Quarter 2019 Financial Results and Provides Business Update

--Announced Issuance of New Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

BTX : 0.92 (-7.08%)
BioTime Announces Issuance of U.S. Patent for Method of Reducing Cavitation in Patients with Acute Spinal Cord Injury

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet needs, announced today the issuance of a Notice of Allowance...

BTX : 0.92 (-7.08%)
BioTime to Report First Quarter 2019 Financial Results and Provide Business Update on May 9, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, today announced that it will report its first quarter 2019 financial...

BTX : 0.92 (-7.08%)
BioTime Presents Updated Data from OpRegen(R) Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced that updated results from a Phase I/IIa clinical study...

BTX : 0.92 (-7.08%)
BioTime to Present Data from OpRegen(R) Phase I/IIa Clinical Study at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2019)

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing new cellular therapies, announced today that updated results from a Phase I/IIa clinical...

BTX : 0.92 (-7.08%)
BioTime (BTX) Upgraded to Strong Buy: Here's What You Should Know

BioTime (BTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

BTX : 0.92 (-7.08%)
New Research Coverage Highlights BioMarin Pharmaceutical, EnLink Midstream, GCI Liberty, Vistra Energy, BioTime, and Karyopharm Therapeutics -- Consolidated Revenues, Company Growth, and Expectations for 2019

In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders, and shareholders of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN),...

BMRN : 85.89 (+1.50%)
ENLC : 5.45 (+1.68%)
GLIBA : 72.08 (-0.04%)
VST : 21.54 (-0.51%)
BTX : 0.92 (-7.08%)
KPTI : 16.97 (+6.90%)
Top Ranked Momentum Stocks to Buy for April 2nd

Top Ranked Momentum Stocks to Buy for April 2nd

RLH : 3.01 (-1.31%)
FAST : 35.77 (+1.48%)
BTX : 0.92 (-7.08%)
AZO : 1,107.58 (-0.62%)
AgeX Therapeutics Reports Fourth Quarter and Annual 2018 Financial Results and Provides Business Update

--Potential to generate any human cell type with clinical and commercial friendly characteristics of hypoimmunogenicity, low COGS and availability off-the-shelf

BTX : 0.92 (-7.08%)
BioTime to Present at Oppenheimer & Co. 29th Annual Healthcare Conference on March 20, 2019

BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer,...

BTX : 0.92 (-7.08%)
BioTime Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Business Update

--Completed Distribution of AgeX Therapeutics Shares to BioTime Shareholders

AST : 0.94 (unch)
BTX : 0.92 (-7.08%)
BioTime Announces Closing of Acquisition of Asterias Biotherapeutics Creating Leading Cell Therapy Company

BioTime, Inc. (NYSE American and TASE: BTX), today announced the closing of its previously reported acquisition of Asterias Biotherapeutics, Inc. (Asterias), whereby BioTime has acquired...

AST : 0.94 (unch)
BTX : 0.92 (-7.08%)

Van Meerten Stock Picks

My 5 Favorite Mid Caps
Summary 100% technical buy signals with current momentum.
CRUS +2.63 , SEDG +7.11 , THC +1.13 , TER +1.66 , LITE +1.85
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.

InsideFutures Commentary

InsideFutures is a twice weekly newsletter that features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Wednesday and Friday morning to your inbox.

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar